Ito Zensho, Takakura Kazuki, Suka Machi, Kanai Tomoya, Saito Ryota, Fujioka Shuichi, Kajihara Mikio, Yanagisawa Hiroyuki, Misawa Takeyuki, Akiba Tadashi, Koido Shigeo, Ohkusa Toshifumi
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine, Kashiwa Hospital, Kashiwa, Chiba 277-8564, Japan.
Department of Public Health and Environmental Medicine, Jikei University School of Medicine, Tokyo 105-8461, Japan.
Oncol Lett. 2017 Jun;13(6):4799-4805. doi: 10.3892/ol.2017.6071. Epub 2017 Apr 21.
Patients with pancreatic ductal adenocarcinoma (PDA) typically succumb to mortality early, even following surgical resection. Therefore, prognostic factors associated with early mortality are required to improve the survival of patients with PDA following surgical resection. Carbohydrate sulfotransferase 15 (CHST15) is responsible for the biosynthesis of sulfated chondroitin sulfate E (CS-E), which serves a pivotal function in cancer progression by cleaving CD44. CHST15 and CD44 expression in PDA tissue were assessed as a prognostic factor in patients with PDA following surgical resection. A total of 36 consecutive patients with PDA were enrolled following surgical resection between January 2008 and December 2014. The intensities of CHST15 and CD44 expression were analyzed by immunohistochemical staining. The recurrence period was significantly earlier in the strong CHST15 expression group compared with the negative-to-moderate CHST15 expression group. Overall survival (OS) was also significantly decreased in the strong CHST15 expression group compared with the negative-to-moderate CHST15 expression group. Multivariate analysis also indicated significant associations between CHST15 overexpression and disease-free survival (DFS) and OS. However, expression of CD44 in PDA tissue was not associated with DFS or OS. The present study has demonstrated for the first time that high CHST15 expression in PDA tissue may represent a potential predictive marker of DFS and OS in patients with PDA following surgical resection.
胰腺导管腺癌（PDA）患者通常即使在手术切除后也会过早死亡。因此，需要与早期死亡率相关的预后因素来提高PDA患者手术切除后的生存率。碳水化合物硫酸转移酶15（CHST15）负责硫酸化硫酸软骨素E（CS-E）的生物合成，CS-E通过切割CD44在癌症进展中起关键作用。评估PDA组织中CHST15和CD44的表达作为手术切除后PDA患者的预后因素。2008年1月至2014年12月期间，共有36例连续的PDA患者在手术切除后入组。通过免疫组织化学染色分析CHST15和CD44表达的强度。与CHST15阴性至中度表达组相比，CHST15强表达组的复发期明显更早。与CHST15阴性至中度表达组相比，CHST15强表达组的总生存期（OS）也显著降低。多变量分析还表明CHST15过表达与无病生存期（DFS）和OS之间存在显著关联。然而，PDA组织中CD44的表达与DFS或OS无关。本研究首次证明，PDA组织中CHST15高表达可能是手术切除后PDA患者DFS和OS的潜在预测标志物。
